Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash & Current Investments: 2023-2025

Historic Cash & Current Investments for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $272.6 million.

  • Immunome's Cash & Current Investments rose 13.52% to $272.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 11.28%. This contributed to the annual value of $217.3 million for FY2024, which is 57.30% up from last year.
  • According to the latest figures from Q3 2025, Immunome's Cash & Current Investments is $272.6 million, which was up 1.69% from $268.1 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Cash & Current Investments ranged from a high of $317.3 million in Q1 2025 and a low of $38.4 million during Q2 2023.
  • Moreover, its 3-year median value for Cash & Current Investments was $240.2 million (2024), whereas its average is $201.4 million.
  • In the last 5 years, Immunome's Cash & Current Investments skyrocketed by 624.58% in 2024 and then declined by 3.68% in 2025.
  • Immunome's Cash & Current Investments (Quarterly) stood at $138.1 million in 2023, then soared by 57.30% to $217.3 million in 2024, then increased by 13.52% to $272.6 million in 2025.
  • Its Cash & Current Investments stands at $272.6 million for Q3 2025, versus $268.1 million for Q2 2025 and $317.3 million for Q1 2025.